Michael Girardi
Affiliations: | Yale School of Medicine | Yale University, New Haven, CT |
Area:
Cell Biology, OncologyGoogle:
"Michael Girardi"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Girardi M, Carlson K, Huang X, et al. (2024) Chart review study of real-world clinical outcomes in patients with cutaneous T-cell lymphoma treated with extracorporeal photopheresis in the US in 2017-2019. The Journal of Dermatological Treatment. 35: 2360568 |
| Ren J, Liao X, Lewis JM, et al. (2024) Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy. Nature Communications. 15: 519 |
| Avery J, Kim SR, Cheng W, et al. (2023) FISH Panel for Leukemic Cutaneous T-Cell Lymphoma: Extended Patient Cohort Correlation with Blood Involvement and Clinical Outcomes. Jid Innovations : Skin Science From Molecules to Population Health. 3: 100212 |
| Yu B, Kim SR, Roy SF, et al. (2023) A rare presentation of cutaneous T-cell lymphoma mimicking morphea. Jaad Case Reports. 33: 59-61 |
| Ren J, Qu R, Rahman NT, et al. (2022) Integrated transcriptome and trajectory analysis of cutaneous T-cell lymphoma identifies putative precancer populations. Blood Advances |
| Dehner CA, Ruff WE, Greiling T, et al. (2021) Malignant T Cell Activation by a Species Isolated from Cutaneous T-Cell Lymphoma Lesions. Jid Innovations : Skin Science From Molecules to Population Health. 2: 100084 |
| King ALO, Mirza FN, Lewis JM, et al. (2021) B-cell lymphoma 2 inhibitor venetoclax treatment of a patient with cutaneous T-cell lymphoma. Jaad Case Reports. 8: 89-92 |
| Mirza FN, Yumeen S, Girardi M. (2020) Disparities in Outcomes of CD8+ Cutaneous T Cell Lymphoma by Race and Presenting Lesion Location British Journal of Dermatology. 184: 170-171 |
| Isufi I, Seropian S, Gowda L, et al. (2020) Outcomes for allogeneic stem cell transplantation in refractory mycosis fungoides and primary cutaneous gamma Delta T cell lymphomas. Leukemia & Lymphoma. 1-7 |
| Yumeen S, Mirza FN, Lewis JM, et al. (2020) JAK inhibition synergistically potentiates BCL2, BET, HDAC, and proteasome inhibition in advanced CTCL. Blood Advances. 4: 2213-2226 |